Publications | Lund University Publications

1 – 7 of 7

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=author%3D%22%C3%98stenstad%2C+B%22+or+(documentType+any+%22bookEditor+conferenceEditor%22+and+editor%3D%22%C3%98stenstad%2C+B%22)&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2013
Mark Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Holte, H. ; Leppa, S. ; Bjorkholm, M. ; Fluge, O. ; Jyrkkio, S. ; Delabie, J. ; Sundstrom, C. ; Karjalainen-Lindsberg, M. -L. ; Erlanson, M. and Kolstad, A. , et al. (2013) In Annals of Oncology 24(5). p.1385-1392
- Contribution to journal › Article
2002
Mark Tumour microvessel density as predictor of chemotherapy response in breast cancer patients
Tynninen, O ; Sjostrom, J ; von Boguslawski, K ; Bengtsson, NO ; Heikkila, R ; Malmström, Per ^LU ; Ostenstad, B ; Wist, E ; Valvere, V and Saksela, E , et al. (2002) In British Journal of Cancer 86(12). p.1905-1908
- Contribution to journal › Article
Mark C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
Sjostrom, J ; Collan, J ; von Boguslawski, K ; Franssila, K ; Bengtsson, NO ; Mjaaland, I ; Malmström, Per ^LU ; Ostenstad, B ; Wist, E and Valvere, V , et al. (2002) In European Journal of Cancer 38(4). p.535-542
- Contribution to journal › Article
2001
Mark Timing of quality of life (QoL) assessments as a source of error in oncological trials
Hakamies-Blomqvist, L ; Luoma, M L ; Sjöström, J ; Pluzanska, A ; Sjödin, M ; Mouridsen, H ; Østenstad, B ; Mjaaland, I ; Ottosson, S and Bergh, J , et al. (2001) In Journal of Advanced Nursing 35(5). p.709-716
- Contribution to journal › Article
2000
Mark Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
Hakamies-Blomqvist, L ; Luoma, M ; Sjöström, J ; Pluzanska, A ; Sjödin, M ; Mouridsen, H ; Ostenstad, B ; Mjaaland, I ; Ottosson-Lönn, S and Bergh, J , et al. (2000) In European Journal of Cancer 36(11). p.7-1411
- Contribution to journal › Article
1999
Mark Predictive value of P53, MDM-2, P21-expression, KI-67 for response to docetaxel or methotrexate-fluorouracil (MF) in advanced breast cancer
Blomqvist, C. ; Sjöström, J ; von Boguslawski, K ; Heikkila, P ; Bengtsson, N-O ; Mjaaland, I ; Ostenstad, B ; Malmström, P ^LU ; Bergh, J. and Valvere, V , et al. (1999) In Breast Cancer Research and Treatment 57(1). p.61-61
- Contribution to journal › Published meeting abstract
Mark Predictive value c-erB-B2 expression for response to docetaxel (D) or methotrexate-fluorouracil (MF) in advanced breast cancer
Collan, J ; Sjöström, J ; von Boguslawski, K ; Franssila, K ; Bengtsson, N-O ; Mjaaland, I ; Østenstad, B ; Malmström, P ^LU ; Bergh, J. and Valvere, V , et al. (1999) In Breast Cancer Research and Treatment 57(1). p.64-64
- Contribution to journal › Published meeting abstract